Calivirgin

KaliVir Immunotherapeutics is a clinical-stage biotechnology company focused on developing next-generation oncolytic viral immunotherapies. Utilizing its proprietary Vaccinia Enhanced Template (VET™) platform, the company engineers potent oncolytic vaccinia viruses that are optimized for systemic (intravenous) delivery and enhanced tumor selectivity. These viruses are designed to selectively replicate within and destroy tumor cells while simultaneously expressing therapeutic transgenes, such as IL-12 and TGF-beta inhibitors, to stimulate a robust anti-tumor immune response. KaliVir's lead candidate, VET3-TGI, is currently being evaluated in Phase 1/1b clinical trials for the treatment of advanced solid tumors. The company has secured strategic collaborations with industry leaders like Roche and Astellas Pharma to further develop and commercialize its innovative pipeline.